Oxymesterone is a potent oral anabolic steroid derived from testosterone. In structure, it is most closely related to 4-hydroxytestosterone, differing only by the addition of a c-17 alpha methyl group, which makes oral dosing viable. Like its non-methylated analog, oxymesterone remains an effective lean-tissue-building steroid with only a minimal to moderate androgenic component. It has no known estrogenic or progestational activity, and no discernable ability to cause side effects related to female sex hormones. Oxymesterone is a "clean" drug among oral steroids: potent, non-aromatizable, and primarily anabolic in nature. According to the standard laboratory assays, oxymesterone is over three times more anabolic than methyltestosterone, with only half the androgenicity. Closer comparisons to methyltestosterone, which may seem structurally logical, do not hold up well in practice, given the sharp contrasts in relative effects between these drugs. The differences are as drastic as their applications, with methyltestosterone being used almost exclusively for bulking phases of training while oxymesterone would fit most comfortably with cutting cycles or competitive athletics.
|Brand name||Oranabol, Oxymesterone|
Oxymesterone was first closely described in 1956. It was developed into a medicine during the early 1960's by Societa Farmaceutici (Italy), which filed for patent protection on this compound in at least three countries including the United Kingdom, the United States, and Italy. This drug saw limited clinical use as a prescription agent under the Oranabol brand name in Spain and Italy, and under the names Anamidol, Balnimax, Sanabol, and Theranabol in other countries including Japan, the UK, and the Netherlands. Oxymesterone ultimately enjoyed little commercial success, and has been unavailable as a prescription drug worldwide for more than three decades now. It was never released in the United States. At very best, only a small handful of U.S. athletes have experimented with this obscure anabolic steroid over the years, and certainly very few in recent times.
By the 1990's, oxymesterone had already become a forgotten relic of early steroid development. In all this time there has been limited mention of its use in the medical literature. The drug did show up in a report released in 1993 by the department of Clinical Pharmacology and Toxicology at St. Vincent's Hospital in New South Wales, concerning two young football players who died of cardiac events in 1988 and 1990. The two men, who had unobstructed arteries and were only 18 and 24 years of age, died during routine training sessions. Despite never being offered for sale in Australia, and having been removed from the global market long before 1988, oxymesterone had been detected in the men during autopsy. No conclusive link between the drug and their deaths could be established, neither discounted. Today, oxymesterone remains unavailable as a prescription agent worldwide.
How is Oranabol Supplied
Oxymesterone is no longer available as a prescription drug product.
Structural Characteristics of Oranabol
Oxymesterone is a modified form of testosterone. It differs by: 1) the addition of a methyl group at carbon 17-alpha, which helps protect the hormone during oral administration, and 2) the attachment of a hydroxyl group at carbon 4, which inhibits steroid aromatization and reduces relative androgenicity.
Oranabol Side Effects (Estrogenic)
Oxymesterone is not aromatized by the body, and is not measurably estrogenic. An anti-estrogen is not necessary when using this steroid, as gynecomastia should not be a concern even among sensitive individuals. Since estrogen is the usual culprit with water retention, this steroid instead produces a lean, quality look to the physique with no fear of excess subcutaneous fluid retention. This makes it a favorable steroid to use during cutting cycles, when water and fat retention are major concerns.
Note that when a 4-hydroxyl group is applied to testosterone (as in hydroxytestosterone) a suicide aromatase inhibitor is created, capable of significantly suppressing serum estrogen levels. It is unknown if this property exists in Oranabol (methylhydroxytestosterone), as this potential aspect of its pharmacology has never been investigated. Its non-estrogenic and non-progestational profile would support, at the very least, this agent being a steroid for increasing muscle density and visibility, regardless of a related aromatase-inhibiting effect, which may indeed also be present.
Oranabol Side Effects (Androgenic)
Although oxymesterone is classified as an anabolic steroid, androgenic side effects are still possible with this substance.These may include bouts of oily skin, acne, and body/facial hair growth. Doses higher than normally prescribed are more likely to cause such side effects. Anabolic/androgenic steroids may also aggravate male pattern hair loss. Women are additionally warned of the potential virilizing effects of anabolic/androgenic steroids. These may include a deepening of the voice, menstrual irregularities, changes in skin texture,facial hair growth, and clitoral enlargement. Note that oxymesterone is not extensively metabolized by the 5-alpha reductase enzyme, so its relative androgenicity is not greatly altered by the concurrent use of finasteride or dutasteride.
Oranabol Side Effects (Hepatotoxicity)
Oxymesterone is a cl 7-alpha alkylated compound. This alteration protects the drug from deactivation by the liver, allowing a very high percentage of the drug entry into the bloodstream following oral administration. Cl 7-alpha alkylated anabolic/androgenic steroids can be hepatotoxic. Prolonged or high exposure may result in liver damage. In rare instances life-threatening dysfunction may develop. It is advisable to visit a physician periodically during each cycle to monitor liver function and overall health. Intake of cl 7-alpha alkylated steroids is commonly limited to 6-8 weeks, in an effort to avoid escalating liver strain. Note that in studies this agent offered slightly less hepatic strain than methandrostenolone and norethandrolone, as measured by bromosulphalein (BSP) retention.
Oranabol Side Effects (Cardiovascular)
Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to reduce HDL (good) cholesterol values and increase LDL (bad) cholesterol values, which may shift the HDL to LDL balance in a direction that favors greater risk of arteriosclerosis. The relative impact of an anabolic/androgenic steroid on serum lipids is dependant on the dose, route of administration (oral vs. injectable), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Oxymesterone has a strong effect on the hepatic management of cholesterol due to its structural resistance to liver breakdown. and route of administration. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and support left ventricular hypertrophy, all potentially increasing the risk of cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to maintain an active cardiovascular exercise program and minimize the intake of saturated fats, cholesterol, and simple carbohydrates at all times during active AAS administration. Supplementing with fish oils (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with comparable ingredients is also recommended.
Oranabol Side Effects (Testosterone Suppression)
All anabolic/androgenic steroids when taken in doses sufficient to promote muscle gain are expected to suppress endogenous testosterone production. Without the intervention of testosterone-stimulating substances, testosterone levels should return to normal within 1-4 months of drug secession. Note that prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.
The above side effects are not inclusive. For more detailed discussion of potential side effects, see the Steroid Side Effects section of this book.
Oranabol Administration (General)
Prescribing guidelines generally advise that oral steroids can be taken with or without meals. The difference in bioavailability is generally not regarded as substantial. However, a 2016 study on newborn infants did find the absorption of oxandrolone to be significantly improved when dissolved directly in fat (MCT oil). If the diet includes considerable fat content, taking this oral steroid with meals might be more advantageous.
Oranabol Administration (Men)
A common clinical dose for oxymesterone was 20-40 mg per day. In the athletic arena, an effective oral daily dosage also falls in the range of 20-40 mg, taken in cycles lasting no more than 6-8 weeks to minimize hepatotoxicity. This level is sufficient for formidable strength gains, increased fat loss, increased muscle definition, and an overall increase in lean muscle mass. This drug would further stack well with a variety of other steroids, especially a 200-400 mg per week dose of an injectable base like testosterone cypionate/enanthate or Equipoise® during bulking phases of training, or a milder anabolic like Deca-Durabolin® or Primobolan® for cutting and defining. All of these stack combinations should work extremely well,and would not add to the liver toxicity already present in oxymesterone.
Oranabol Administration (Women)
A common clinical dose for oxymesterone was 20-40 mg per day. In the athletic arena, women would likely notice substantial gains on 10 mg per day, taken for no longer than 4 weeks. Virilizing side effects are still possible with a powerful hormone like oxymesterone, especially with higher doses, and should be carefully monitored.
This agent has not been sold as a prescription drug in over 30 years, and is presently unavailable.
Wlliam Llewellyn (2017) - Anabolics